Evaluation of Remdesivir for Mildly to Moderately Ill Patients with COVID-19: A Single-Arm, Single-Center, Retrospective Study

<i>Background and Objectives</i>: Remdesivir (RDV) is the first antiviral agent approved in Japan for the treatment of coronavirus disease 2019 (COVID-19). The aim of our study was to assess the efficacy and safety of RDV treatment in mildly to moderately ill patients with COVID-19. <i>Materials and...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Motoyasu Miyazaki, Ryoko Yanagida, Akio Nakashima, Koichi Matsuo, Norihiro Moriwaki, Masanobu Uchiyama, Yota Yamada, Hitomi Hirata, Hisako Kushima, Yoshiaki Kinoshita, Hiroshi Ishii, Osamu Imakyure
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	MDPI AG 2022-07-01
סדרה:	Medicina
נושאים:	coronavirus COVID-19 remdesivir oxygen therapy
גישה מקוונת:	https://www.mdpi.com/1648-9144/58/8/1007
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!